Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.7.1.40: pyruvate kinase

This is an abbreviated version!
For detailed information about pyruvate kinase, go to the full flat file.

Word Map on EC 2.7.1.40

Reaction

ATP
+
pyruvate
=
ADP
 +
phosphoenolpyruvate

Synonyms

ATP/pyruvate O'-phosphotransferase, ATP:pyruvate 2-O-phosphotransferase, CPK, CPK1, cPK2, cPK3, cPK4, cPK5, CTHBP, cytosolic pyruvate kinase, cytosolic thyroid hormone binding protein, EHI_098420, EhPK, EhPyk, erythroid (R-type) pyruvate kinase, fluorokinase, hL-PYK, hLPYK, hPKM2, K+-dependent PK, K+-independent PK, kinase, fluoro- (phosphorylating), kinase, pyruvate (phosphorylating), L-PK , L-PYK, liver PK, liver pyruvate kinase, M1-PK, M1-PYK, M2 pyruvate kinase, M2 type phosphoenolpyruvate kinase, M2-PK, M2-pyruvate kinase, M2-type pyruvate kinase, M2PK, mPKM2, MRSA PK, muscle PK, NCgl2008, NCgl2809, PAE0819, PfPYK, pfPyrK, phosphoenol transphosphorylase, phosphoenolpyruvate kinase, phosphoenolpyruvate: ADP phosphotransferase, PK-alphabeta1, PK-alphabeta2, PK-M1, PK-M2, PK-R, PK-S, PK1, PK3, PKC, PKC1, PKL, Pklr, PKM1, PKM2, PKp, ProTalphaK, PYK, PYK-I, Pyk1, Pyk2, PykA, PykF, PyKII, pyruvate kinase, pyruvate kinase 1, pyruvate kinase isoenzyme M2, pyruvate kinase isoform M2, pyruvate kinase isoforms 2, pyruvate kinase isozyme M1, pyruvate kinase isozyme type M2, pyruvate kinase M1, pyruvate kinase M2, pyruvate kinase M2 isoform, pyruvate kinase muscle isoform 2, pyruvate kinase muscle isozyme, pyruvate kinase type M2, pyruvate kinase type-II, pyruvate phosphotransferase, pyruvic kinase, R-type pyruvate kinase, R-type/L-type pyruvate kinase, red cell/liver pyruvate kinase, rM1-PYK, RMPK, RPK, Rv1617, SSO0981, TbrPYK, TCIL3000_10_12020, TcoPYK, THBP1, TuM2-PK, tumor cell specific pyruvate kinase isozyme M2, tumour M2-PK, tumour M2-pyruvate kinase, VcIIPK, VcIPK, VC_0485, VC_2008, VEG17, vegetative protein 17, vesicle-associated pyruvate kinase, YPK

ECTree

     2 Transferases
         2.7 Transferring phosphorus-containing groups
             2.7.1 Phosphotransferases with an alcohol group as acceptor
                2.7.1.40 pyruvate kinase

Inhibitors

Inhibitors on EC 2.7.1.40 - pyruvate kinase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1,4-dimethoxynaphthalen-2-yl)methyl dipropylcarbamodithioate
-
(1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl diethylcarbamodithioate
-
(1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl morpholine-4-carbodithioate
-
(1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl piperidine-1-carbodithioate
-
(1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl [4-(piperazin-1-yl)phenyl]carbamodithioate
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) bis(diethylcarbamodithioate)
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) bis(dimethylcarbamodithioate)
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) bis(diprop-2-en-1-ylcarbamodithioate)
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) bis(dipropylcarbamodithioate)
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) di(1,3-thiazolidine-3-carbodithioate)
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) dimorpholine-4-carbodithioate
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) dipyrrolidine-1-carbodithioate
-
(1,4-dioxo-1,4-dihydronaphthalene-2,3-diyl)bis(methylene) dithiomorpholine-4-carbodithioate
-
(1S,3S)-1,3-di(1H-indol-3-yl)-1,2,3,4-tetrahydrocyclopenta[b]indole
-
-
(1S,3S)-2-bromo-1,3-di(1H-indol-3-yl)-1,2,3,4-tetrahydrocyclopenta[b]indole
-
-
(1S,3S)-2-chloro-1,3-di(1H-indol-3-yl)-1,2,3,4-tetrahydrocyclopenta[b]indole
-
-
(1S,4S)-1,4-di(1H-indol-3-yl)-2,3,4,9-tetrahydro-1H-carbazole
-
-
(1S,4S)-6-chloro-1,4-bis(5-chloro-1H-indol-3-yl)-2,3,4,9-tetrahydro-1H-carbazole
-
-
(2'E)-2,2'-(1E,3E)-prop-1-en-1-yl-3-ylidenebis(1-butyl-5,6-dichloro-3-pentyl-2,3-dihydro-1H-benzimidazole)
-
86% inhibition at 0.03 mM
(2-[(1E)-1-[2-(5-bromo-2-hydroxybenzoyl)hydrazinylidene]ethyl]-1-methyl-1H-indol-6-yl)dibromanium
-
-
(2E)-1,3-bis(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
6% inhibition at 0.001 mM
(2E)-1-(3-bromo-2-hydroxyphenyl)-3-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
41% inhibition at 0.001 mM
(2E)-1-(4-bromo-2-hydroxyphenyl)-3-(1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-1-(4-bromo-2-hydroxyphenyl)-3-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-1-(4-methoxyphenyl)-3-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
-
-
(2E)-1-(5-bromo-1H-indol-2-yl)-3-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
21% inhibition at 0.001 mM
(2E)-1-(5-bromo-2-hydroxyphenyl)-3-(1H-indol-2-yl)prop-2-en-1-one
-
10% inhibition at 0.001 mM
(2E)-1-(5-bromo-2-hydroxyphenyl)-3-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
15% inhibition at 0.001 mM
(2E)-1-(6-bromo-1H-indol-2-yl)-3-(1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-1-(6-bromo-1H-indol-2-yl)-3-(5-bromo-2-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-2-[(5-bromo-2-methoxyphenyl)methylidene]-2,3,4,9-tetrahydro-1H-carbazol-1-one
-
22% inhibition at 0.001 mM
(2E)-3-(3-bromo-2-hydroxyphenyl)-1-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-3-(4-bromo-2-hydroxyphenyl)-1-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-1H-indol-3-yl)-1-(1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-2-hydroxyphenyl)-1-(1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-3-(5-bromo-2-hydroxyphenyl)-1-(6-bromo-1H-indol-2-yl)prop-2-en-1-one
-
-
(2E)-3-(6-bromo-1H-indol-2-yl)-1-(1H-indol-2-yl)prop-2-en-1-one
-
38% inhibition at 0.001 mM
(2E)-3-(6-bromo-1H-indol-2-yl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(6-bromo-1H-indol-3-yl)-1-(1H-indol-2-yl)prop-2-en-1-one
-
45% inhibition at 0.001 mM
(2E)-3-(6-bromo-1H-indol-3-yl)-1-(1H-indol-3-yl)prop-2-en-1-one
-
28% inhibition at 0.001 mM
(2R,3S)-2-(3,4-diphenoxyphenyl)-3,5,7-triphenoxy-3,4-dihydro-2H-1-benzopyran
-
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl (4-methylpiperidin-1-yl)carbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl 1,3-thiazolidine-3-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl 3,5-dimethylmorpholine-4-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl 4-(propan-2-yl)piperazine-1-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl 4-acetylpiperazine-1-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl 4-methylpiperazine-1-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl benzylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl bis(2-hydroxyethyl)carbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl cyclohexyl(methyl)carbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl dibutylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl diethylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl diprop-2-en-1-ylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl dipropylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl methylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl morpholine-4-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl piperidin-1-ylcarbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl piperidine-1-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl pyrrolidine-1-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl thiomorpholine-4-carbodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl [(pyridin-2-yl)methyl]carbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl [(pyridin-3-yl)methyl]carbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl [(pyridin-4-yl)methyl]carbamodithioate
-
(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methyl [2-(diethylamino)ethyl]carbamodithioate
-
(5-bromo-2-hydroxyphenyl)([(E)-[1-(1-methyl-1H-indol-2-yl)ethylidene]amino]oxy)methanone
-
34% inhibition at 0.01 mM
(5-bromo-2-methoxyphenyl)([(E)-[1-(1-methyl-1H-indol-2-yl)ethylidene]amino]oxy)methanone
-
33% inhibition at 0.01 mM
(6R,10S)-2-chloro-6,10-bis(5-chloro-1H-indol-3-yl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole
-
-
(6R,10S)-3-chloro-6,10-bis(6-chloro-1H-indol-3-yl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole
-
-
(6R,10S)-6,10-di(1H-indol-3-yl)-5,6,7,8,9,10-hexahydrocyclohepta[b]indole
-
-
(6R,11S)-6,11-di(1H-indol-3-yl)-6,7,8,9,10,11-hexahydro-5H-cycloocta[b]indole
-
-
(E)-5-bromo-2-hydroxy-N'-(1-(4,5,6-trifluoro-1Hindol-2-yl)ethylidene)benzohydrazide
-
-
(E)-5-bromo-2-hydroxy-N'-(1-(5-hydroxy-1H-indol-2-yl)ethylidene)benzohydrazide
-
-
(E)-5-bromo-2-hydroxy-N'-(1-(5-methoxy-1H-indol-2-yl)ethylidene)benzohydrazide
-
-
(E)-5-bromo-N'-(1-(4,5-difluoro-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(5,6-difluoro-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(5-bromo-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(5-bromo-1H-indol-2-yl)propylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(5-chloro-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(5-fluoro-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(6-bromo-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-5-bromo-N'-(1-(7-fluoro-1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
39% inhibition at 500 nM
(E)-N'-((1H-indol-2-yl)methylene)-5-bromo-2-hydroxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-2-hydroxy-5-chlorobenzohydrazide
-
36% inhibition at 0.001 mM
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-2-hydroxy-5-iodobenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-2-hydroxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-3,5-dibromo-2-hydroxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-3,5-dibromo-2-methoxybenzohydrazide
-
57% inhibition at 0.001 mM
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-3-bromobenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-4-bromo-2-hydroxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-5-bromo-2-(prop-2-ynyloxy)benzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-5-bromo-2-hydroxy-4-methoxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-5-bromo-2-hydroxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)-5-bromo-2-methoxybenzohydrazide
-
-
(E)-N'-(1-(1H-indol-2-yl)ethylidene)benzohydrazide
-
28% inhibition at 0.01 mM
(E)-N'-(1-(1H-indol-2-yl)ethylidene)picolinohydrazid
-
15% inhibition at 0.01 M
(E)-N'-(1-(1H-indol-2-yl)propylidene)-5-bromo-2-hydroxybenzohydrazide
-
crystal structure determination of the inhibitor compound
(E)-N'-[(1H-indol-2-yl)methylene]-5-bromo-2-methoxybenzohydrazide
-
-
(E)-N'-[1-(1H-indol-2-yl)ethylidene]-2-hydroxy-3,5-diisopropylbenzohydrazide
-
40% inhibition at 0.01 mM
(E)-N'-[1-(1H-indol-2-yl)ethylidene]-5-bromo-2-ethoxybenzohydrazide
-
-
(E/Z)-N'-((1H-indol-2-yl)(phenyl)methylene)-5-bromo-2-hydroxybenzohydrazide
-
-
(Z)-N'-(1-(1H-indol-2-yl)-2,2-dimethylpropylidene)-5-bromo-2-hydroxybenzohydrazide
-
crystal structure determination of the inhibitor compound
1-(6-bromo-1-benzothiophen-2-yl)-2-(4-bromophenyl)ethan-1-one
-
43% inhibition at 0.001 mM
1-(6-bromo-1H-indol-2-yl)-2-(4-bromophenyl)ethan-1-one
-
-
2,3-diphosphoglycerate
2,4-dihydroxy-N'-[(E)-(2-hydroxy-6,7,8,9-tetrahydrodibenzo[b,d]furan-1-yl)methylidene]benzohydrazide
-
-
2-(3-bromo-2-hydroxyphenyl)-1-(6-bromo-1H-indol-2-yl)ethan-1-one
-
-
2-(4-bromophenyl)-1-(1H-indol-2-yl)ethan-1-one
-
41% inhibition at 0.001 mM
2-(5-bromo-1H-benzimidazol-2-yl)-1-(5-bromo-1H-indol-2-yl)ethan-1-one
-
-
2-(5-bromo-1H-benzimidazol-2-yl)-1-(5-bromo-2-hydroxyphenyl)ethan-1-one
-
-
2-(5-bromo-1H-benzimidazol-2-yl)-1-(6-bromo-1H-indol-2-yl)ethan-1-one
-
-
2-(5-bromo-2-hydroxyphenyl)-1-(1H-indol-2-yl)ethan-1-one
-
28% inhibition at 0.001 mM
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(1-methyl-1H-indol-2-yl)ethan-1-one
-
41% inhibition at 0.001 mM
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(1H-indol-2-yl)ethan-1-one
-
-
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(3-bromo-2-hydroxyphenyl)ethan-1-one
-
-
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(3-bromo-2-methoxyphenyl)ethan-1-one
-
22% inhibition at 0.001 mM
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(3-chloro-2-hydroxyphenyl)ethan-1-one
-
43% inhibition at 0.001 mM
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(4-bromo-2-hydroxyphenyl)ethan-1-one
-
-
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(5-bromo-1H-indol-2-yl)ethan-1-one
-
-
2-(6-bromo-1,3-benzothiazol-2-yl)-1-(5-bromo-2-methoxyphenyl)ethan-1-one
-
-
2-aminoisobutyric acid
-
allosteric inhibition
2-bromo-6-[[(6-bromo-1,3-benzothiazol-2-yl)amino]methyl]phenol
-
17% inhibition at 0.001 mM
2-hydroxy-5-iodo-N'-[(1E)-1-(1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
-
2-oxoglutarate
2-phosphoglycerate
-
only isozyme PKp, not PKc
2-tetradecylglycidic acid
-
in mice treated with 2-tetradecylglycidic acid, hepatic pyruvate kinase mRNA levels are significantly decreased, whereas pyruvate dehydrogenase kinase isozyme 4 expression is 30fold increased
2-[(1E)-1-[2-[(5-bromo-2-methoxyphenyl)(dioxido-l6-sulfanylidene)methyl]hydrazinylidene]ethyl]-1H-indole
-
12% inhibition at 0.01 mM
2-[(1E)-1-[2-[(5-bromo-2-methoxyphenyl)(dioxido-l6-sulfanylidene)methyl]hydrazinylidene]ethyl]-4,5-difluoro-1H-indole
-
11% inhibition at 0.01 mM
2-[5-(5-bromo-2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]-1H-indole
-
19% inhibition at 0.001 mM
2-[6-(5-bromo-2-methoxyphenyl)pyridin-2-yl]-1H-indole
-
6% inhibition at 0.001 mM
3,5-diphenoxy-2-[(2E)-3-(3,4,5-triphenoxyphenyl)prop-2-en-1-yl]phenol
-
-
3-(2,5-dimethylphenoxy)-1,2-benzothiazole 1,1-dioxide
-
a saccharin derivative, potent inhibitor, but a labile compound
3-(2-hydroxy-4-methoxyphenyl)-1-(4-methoxyphenyl)propane-1,2-diol
-
-
3-hydroxy-N'-[(1E)-1-(1H-indol-2-yl)ethylidene]naphthalene-2-carbohydrazide
-
-
3-hydroxy-N'-[(1E)-1-(4,5,6-trifluoro-1-methyl-1H-indol-2-yl)ethylidene]naphthalene-2-carbohydrazide
-
-
3-hydroxy-N'-[(1E)-1-(4,5,6-trifluoro-1-methyl-1H-indol-2-yl)propylidene]naphthalene-2-carbohydrazide
-
-
3-hydroxy-N'-[(1E)-1-(4,5,6-trifluoro-1H-indol-2-yl)propylidene]naphthalene-2-carbohydrazide
-
-
3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl 4-acetylpiperazine-1-carbodithioate
-
3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl dipropylcarbamodithioate
-
3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl morpholine-4-carbodithioate
-
3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl piperidine-1-carbodithioate
-
3-oxo-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propyl [(pyridin-3-yl)methyl]carbamodithioate
-
3-oxo-3-phenylpropyl [(pyridin-3-yl)methyl]carbamodithioate
-
3-phosphoglycerate
3-[(2,5-dimethylphenyl)sulfanyl]-1,2-benzothiazole 1,1-dioxide
-
a stable sulfur derivative of 3-(2,5-dimethylphenoxy)-1,2-benzothiazole 1,1-dioxide
3-[4-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)-1,4-diazepane-1-sulfonyl]aniline
-
4-amino-2-methylnaphthalen-1-ol
-
i.e. vitamin K5, shows a significantly stronger potency to inhibit isozyme PKM2 than to inhibit isozymes PKM1 and PKL
4-bromo-2-hydroxy-N'-[(1E)-1-(1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
611% inhibition at 500 nM
4-bromo-2-[(E)-[(6-bromo-1,3-benzothiazol-2-yl)imino]methyl]phenol
-
41% inhibition at 0.001 mM
4-bromo-2-[2-(6-bromo-1H-indol-2-yl)pyridin-4-yl]phenol
-
41% inhibition at 0.001 mM
4-bromo-2-[5-(1H-indol-2-yl)-1,3,4-oxadiazol-2-yl]phenol
-
8% inhibition at 0.001 mM
4-hydroxy-N'-(7-hydroxy-2,3-dihydro-8H-[1,4]dioxino[2,3-f]indol-8-yl)phthalazine-1-carbohydrazide
-
-
4-hydroxy-N'-[(1E)-1-(1H-indol-2-yl)ethylidene]-1,10-biphenyl-3-carbohydrazide
-
20% inhibition at 0.01 mM
4-[(1,1-dioxo-1,2-benzothiazol-3-yl)sulfanyl]benzoic acid
-
irreversible inhibitor, a saccharin derivative, reacts with an active-site lysine residue (Lys335), forming a covalent bond and sterically hindering the binding of ADP/ATP, covalent inhibitor mechanism, overview. Inhibition of LmPYK by the compound is time-dependent
4-[(4-[3-[(1-hydroxy-2-methylpropan-2-yl)sulfamoyl]-4-methylphenyl]phthalazin-1-yl)amino]-N-methylbenzamide
-
-
5,7-diphenoxy-2-(3,4,5-triphenoxyphenyl)-2H-1-benzopyran
-
-
5-(2,3-dihydro-1,4-benzodioxine-6-sulfonyl)-2-(methanesulfonyl)-2,3-dihydro-1H-isoindole
-
5-(2,5-dimethyl-1H-pyrrol-1-yl)-2-hydroxybenzoic acid
-
81% inhibition at 0.03 mM
5-bromo-2-(4-bromophenyl)-1H-indole
-
21% inhibition at 0.001 mM
5-bromo-2-(6-bromo-1,3-benzothiazol-2-yl)-1H-isoindole-1,3(2H)-dione
-
34% inhibition at 0.001 mM
5-bromo-2-(ethoxymethoxy)-N'-((1E)-1-(1H-indol-2-yl)ethylidene)benzohydrazide
-
-
5-bromo-2-hydroxy-4-methoxy-N'-[(1E)-1-(1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(1-methyl-1H-benzimidazol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(1-methyl-1H-indol-2-yl)propylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(1H-indol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(1H-indol-2-yl)propylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(4,5,6-trifluoro-1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(5-hydroxy-1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(5-iodo-1H-indol-2-yl)ethylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(1E)-1-(5-methoxy-1-methyl-1H-indol-2-yl)ethylidene]benzohydrazide
-
54% inhibition at 0.001 mM
5-bromo-2-hydroxy-N'-[(1E)-1-[5-(trifluoromethyl)-1Hindol-2-yl]ethylidene]benzohydrazide
-
46% inhibition at 0.01 mM
5-bromo-2-hydroxy-N'-[(3E)-5-methyl-2-methylidene-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(E)-(1-methyl-1H-indol-2-yl)(phenyl)methylidene]benzohydrazide
-
-
5-bromo-2-hydroxy-N'-[(E)-(1-methyl-1H-indol-2-yl)methylidene]benzohydrazide
-
-
5-bromo-3-(4-bromophenyl)-1H-indole
-
20% inhibition at 0.001 mM
5-bromo-N'-[(1E)-1-(1H-indol-2-yl)ethylidene]-2-methoxy-N-methylbenzohydrazide
-
33% inhibition at 0.001 mM
5-bromo-N'-[(1E)-1-(2,4-dihydroxyphenyl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(4,5-difluoro-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(5,6-difluoro-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(5,6-difluoro-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(5-bromo-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(5-bromo-1-methyl-1H-indol-2-yl)propylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(5-chloro-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(5-fluoro-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(6-bromo-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(6-chloro-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(6-fluoro-1-methyl-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(1E)-1-(6-fluoro-1H-indol-2-yl)ethylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N'-[(3E)-5-bromo-2-methylidene-1,2-dihydro-3H-indol-3-ylidene]-2-hydroxybenzohydrazide
-
-
5-bromo-N-(5-bromo-1,3-benzothiazol-2-yl)-1H-indole-2-carboxamide
-
-
5-bromo-N-(6-bromo-1,3-benzothiazol-2-yl)-2-hydroxy-N-methylbenzamide
-
5% inhibition at 0.001 mM
5-bromo-N-(6-bromo-1,3-benzothiazol-2-yl)-2-hydroxybenzamide
-
-
6-bromo-3-(4-bromophenyl)-1H-indole
-
-
6-phosphogluconate
-
-
6-[(3-aminophenyl)methyl]-4-methyl-2-[methyl(methylidene)-lambda4-sulfanyl]-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one
-
7-[(1H-benzimidazol-1-yl)methyl]-2,3-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one
-
A-Raf protein
proteins known for cellular growth and proliferation such as A-Raf and PML protein are known to downregulate PKM2 activity by interacting with it
-
adenine
-
weak
adenosine
-
0.01 mM
ADP-Cr2+
Ala
-
slight
alkannin
-
-
Antibody
-
to bovine type L-kinase leading to partial inactivation of type K-kinase, not type M-kinase, to bovine, chicken and salmon type M-kinases leading partial inactivation of type K-kinase, to bovine type M-kinase leading to partial inactivation of type M-kinase
-
arginine phosphate
ascorbate
-
treatment of rabbit muscle pyruvate kinase with 10 mM ascorbate causes an inactivation with the cleavage of peptide bond. The inactivation or fragmentation of the enzyme is prevented by addition of Mg2+, catalase, and mannitol, but ADP and PEP the substrates do not show any effect
aspartate
-
only isozyme PKp, not PKc
Ba2+
-
in decreasing order of inhibitory efficiency: Ni2+, Zn2+, Cu2+, Ca2+, Ba2+
bromodeoxytopsentin
-
-
Carbamoyl phosphate
-
-
catecholamine
-
-
cis-3-4-dihydrohamacanthin B
-
-
citrate
cumene hydroperoxide
-
1% residual activity after treatment with 17 mM cumene hydroperoxide at 50°C and pH 7 for 2 h
cysteine
-
fructose 1,6-diphosphate protects
cystine
D-alanine
-
allosteric inhibition
D-fructose 1,6-bisphosphate
D-Fructose 1-phosphate
allosteric inhibitor with a 40% reduction in the Vmax
D-glucose 1-phosphate
allosteric inhibitor with a 40% reduction in the Vmax
D-ribose 5-phosphate
-
only isozyme PKp, not PKc
D-ribulose 1,5-bisphosphate
-
isozyme PKp, not PKc
D-serine
-
-
diphosphate
-
IC50: 9.8 mM at pH 6.4, IC50: 17.2 mM at pH 7.4
EGMVLPTVWQPANWMCRLSN
-
peptide aptamer placed within thioredoxin A. Aptamer specifically binds to M2 pyruvate kinase and shifts the isoenzyme into its low affinity dimeric conformation
EGQLRHWGWAWSLASQNFSI
-
peptide aptamer placed within thioredoxin A. Aptamer specifically binds to M2 pyruvate kinase and shifts the isoenzyme into its low affinity dimeric conformation
FeSO4
-
treatment of rabbit muscle pyruvate kinase with 0.02 mM FeSO4 causes an inactivation with the cleavage of peptide bond. The inactivation or fragmentation of the enzyme is prevented by addition of Mg2+, catalase, and mannitol, but ADP and PEP the substrates do not show any effect
fructose 1,6-diphosphate
glucagon
-
-
glucose 6-phosphate
glutamate
-
IC50: 2.5 mM at pH 6.4, IC50: 1.2 mM at pH 7.4
glyoxylate
-
5 mM, 79% of activity remaining; 5 mM, 83% of activity remaining
guanidine hydrochloride
-
GnHCl
hexanoate
-
0.5 mM
Highly phosphorylated inositol derivatives
Pigeon
-
-
-
human papillomavirus-16 E7
causes dissociation of PKM2 tetramer into inactive dimer
-
hydrogen peroxide
-
inhibitory at 0.25%, at pH 7
hydroxyl radical
-
inactivation
iso-citrate
-
10 mM, 70% of activity remaining; 10 mM, 75% of activity remaining
isocitrate
K+
-
above 100 mM, activates below
L-Ala
L-alanine
L-aspartate
31% inhibition at 0.2 mM, cPK1; 6% inhibition at 0.2 mM, cPK3
L-cysteine
L-glutamate
L-lactate
L-Phe
L-phenylalanine
L-proline
-
allosteric inhibition
L-tryptophan
-
1 mM, significant inhibition
L-valine
lysophosphatidic acid
-
malate
menadione
-
i.e. vitamin K3, shows a significantly stronger potency to inhibit isozyme PKM2 than to inhibit isozymes PKM1 and PKL
MgATP2-
monensin
-
0.0005 mM
N'-[(1E)-1-(1,3-benzothiazol-2-yl)ethylidene]-5-bromo-2-hydroxybenzohydrazide
-
-
N'-[(1E)-1-(1,3-benzoxazol-2-yl)ethylidene]-5-bromo-2-hydroxybenzohydrazide
-
26% inhibition at 500 nM
N'-[(1E)-1-(1-benzothiophen-2-yl)ethylidene]-5-bromo-2-hydroxybenzohydrazide
-
-
N'-[(1E)-1-(1H-benzimidazol-2-yl)ethylidene]-5-bromo-2-hydroxybenzohydrazide
-
-
N'-[(1E)-1-(1H-benzimidazol-2-yl)propylidene]-5-bromo-2-hydroxybenzohydrazide
-
-
N'-[(1E)-1-(2,4-dihydroxyphenyl)ethylidene]-3-(5,6-dimethyl-1,3-dihydro-2H-isoindol-2-yl)benzohydrazide
-
-
N'-[(1E)-1-(5-bromo-1-methyl-1H-indol-2-yl)ethylidene]-3-hydroxynaphthalene-2-carbohydrazide
-
-
N'-[(1E)-1-(5-bromo-1-methyl-1H-indol-2-yl)propylidene]-3-hydroxynaphthalene-2-carbohydrazide
-
-
N'-[(1E)-1-(5-bromo-1H-indol-2-yl)ethylidene]-3-hydroxynaphthalene-2-carbohydrazide
-
-
N'-[(1E)-1-(5-bromo-1H-indol-2-yl)propylidene]-3-hydroxynaphthalene-2-carbohydrazide
-
-
N'-[(3E)-5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-3-hydroxybenzohydrazide
-
-
N'-[(3Z)-1-ethyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-3-hydroxynaphthalene-2-carbohydrazide
-
-
N,N'-(ethane-1,2-diyl)bis[4-(2,3-dichlorobenzoyl)-1-methyl-1H-pyrrole-2-carboxamide]
-
N-(1,3-benzothiazol-2-yl)-2-hydroxy-5-sulfanylbenzamide
-
13% inhibition at 0.001 mM
N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrrole
-
a PKM2 inhibitor
N-(3-chloro-4-methylphenyl)-7-fluoro-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide
-
N-(4-(3-(pyridin-3-ylmethyl)-2-thioxo-2,3-dihydrothiazol-4-yl)phenyl)quinoline-8-sulfonamide
-
N-(4-(4-hydroxy-3-((2-methoxypyridin-3-yl)methyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-((4-methylpyridin-3-yl)methyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-((6-(3-(methylsulfonyl)phenyl)pyridin-3-yl)methyl)-2-thioxo-thiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(2-(pyridin-3-yl)ethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(imidazo[1,2-a]pyridin-6-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(pyrazin-2-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-1-phenylmethanesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-1H-pyrrolo[2,3-b]pyridine-3-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,4,6-trimethylbenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2-fluorobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2-morpholinobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2-nitrobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2-oxo-1,2,3,4-tetrahydroquinoline-6-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2-oxo-2Hchromene-6-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-3'-nitro-[1,1'-biphenyl]-2-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-3-fluorobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-3-methoxybenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-3-methylbenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-4-cyanobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-4-fluorobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-4-methoxybenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-4-methylbenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-4-nitrobenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-5-chloro-2-methoxybenzenesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-N-methylquinoline-8-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-[1,1'-biphenyl]-2-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)methanesulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)naphthalene-1-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)naphthalene-2-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)quinolone-8-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)thiophene-2-sulfonamide
-
N-(4-(4-hydroxy-3-(pyridin-4-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-(4-hydroxy-3-(quinolin-3-ylmethyl)-2-thioxothiazolidin-4-yl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
-
N-(4-methylphenyl)-2-[(4-sulfamoylphenyl)amino]pyridine-3-carboxamide
-
-
N-(4-[4-hydroxy-3-[(pyridin-3-yl)methyl]-2-sulfanylidene-1,3-thiazolidin-4-yl]phenyl)-2-methylbenzene-1-sulfonamide
-
N-(4-[4-hydroxy-3-[(pyridin-3-yl)methyl]-2-sulfanylidene-1,3-thiazolidin-4-yl]phenyl)benzenesulfonamide
-
N-(5-bromo-1,3-benzothiazol-2-yl)-1H-indole-2-carboxamide
-
-
N-(5-bromo-1,3-benzothiazol-2-yl)-2-hydroxy-5-sulfanylbenzamide
-
48% inhibition at 0.001 mM
N-(6-bromo-1,3-benzothiazol-2-yl)-2-hydroxybenzamide
-
65% inhibition at 0.001 mM
N-(cyclobutylmethyl)-N-[(2-fluoro-4-hydroxyphenyl)methyl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide
-
N-ethylmaleimide
N-[4-[4-(2-methoxyphenyl)piperazine-1-carbonyl]phenyl]quinoline-8-sulfonamide
-
NaF
-
non-specific phosphoenolpyruvate kinase inhibitor
NH4+
-
above 100 mM, activates below
NH4Cl
-
40 mM, 50-60% decrease in activity of recombinant enzyme
oxalate
oxaloacetate
Pb2+
-
lead inhibits pyruvate kinase activity in a dose-dependent manner by interaction with its thiol groups
peptide aptamer 9
-
-
-
peracetic acid
-
1% residual activity after treatment with 4 mM peracetic acid at 25°C and pH 7 for 15 min
phenylalanine
phenylpyruvate
-
competitive with ADP and phosphoenolpyruvate, Ala prevents inhibition
phosphate
phosphoenolpyruvate
Phosphoglycolate
phosphotyrosine peptide
binding of phosphotyrosine peptides to PKM2 results in release of the allosteric activator fructose-1,6-bisphosphate, leading to inhibition of PKM2 enzymatic activity (20–30% inhibition of PKM2 activity in a dose-dependent manner)
-
PML protein
proteins known for cellular growth and proliferation such as A-Raf and PML protein are known to downregulate PKM2 activity by interacting with it
-
Pp60v-src
causes dissociation of PKM2 tetramer into inactive dimer
-
Procion blue MX-R
-
triazine dye, kinetics, ADP or ADP plus Mg2+ protect, not Mg2+ alone
proline
Busycotypus canaliculatum
-
allosteric inhibitor, fructose 1,6-diphosphate restores
pyridoxal 5'-phosphate
-
1 mM
pyruvate
-
product inhibition
quercetin
-
50% inhibition at 0.1 mM
rutin
-
50% inhibition at 0.07 mM
shikonin
silibinin
-
inhibitory to pyruvate kinase, resulting in dose-dependently reduced glycolysis from carbohydrates and a fall in ATP-toADP ratio, together with an increase in lactate-to-pyruvate ratio in perifused hepatocyte
sulfate
suppressor of cytokine signaling 3
-
in dendritic cells the interaction of M2-PK with suppressor of cytokine signaling 3, SOCS3, induces a decrease of M2-PK activity and ATP production as well as an impairment of dendritic cell-based immunotherapy against tumors
-
t-butyl hydroperoxide
-
in hemolysate exposed to t-butyl hydroperoxide, pyruvate kinase activity decreases along with depletion of glutathione. The addition of glutathione, but not glucose, before exposure completely prevents the inactivation of pyruvate kinase, partial reactivation of inactivated pyruvate kinase is observed by post-addition of both glutathione and glutaredoxin
tert-butyl hydroperoxide
-
1% residual activity after treatment with 290 mM tert-butyl hydroperoxide at 50°C and pH 7 for 3 h
threonine
-
fructose 1,6-diphosphate protects
tryptophan
tyrosine
valine
-
fructose 1,6-diphosphate protects
[(5Z)-5-(4-[[(2-iodophenyl)carbonyl]oxy]benzylidene)-4-oxo-2-thioxo-1,3-thiazolidin-3-yl]acetic acid
-
84% inhibition at 0.03 mM
additional information
-